Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals US Inc. today announced that, effective immediately, CVS is covering QUVIVIQ® (daridorexant) CIV on the Performance Drug List (PDL).
ALLSCHWIL, Switzerland and RADNOR, Pa., July 10, 2023 /PRNewswire/ -- Idorsia Ltd (SIX: IDIA) and Idorsia Pharmaceuticals US Inc. today announced that, effective immediately, CVS is covering QUVIVIQ® (daridorexant) CIV on the Performance Drug List (PDL). Approximately 20 million people are enrolled in this CVS plan, providing increased access to QUVIVIQ for the millions of adults who can benefit from this latest prescription insomnia therapy. QUVIVIQ is now covered by two of the largest insurance plans in the US, Express Scripts and CVS, and several associated regional plans, as well as TRICARE, the healthcare program for active and retired US military personnel and their families.
QUVIVIQ was approved in January 2022 for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.1 It is a dual orexin receptor antagonist (DORA), which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain. Since availability of the product in May 2022, QUVIVIQ has quickly gained traction with patients and physicians, and more than 180,000 prescriptions have been dispensed to date. Sleep is overwhelmingly seen as the third pillar of health, alongside diet and exercise. Poor quality or insufficient sleep can affect many aspects of the daily lives of people with trouble sleeping including the ability to concentrate, mood and energy levels.2 Patty Torr, Idorsia US President and General Manager, commented: In the long-term, insomnia is associated with numerous serious health conditions, such as psychiatric disorders, cardiovascular disease, type 2 diabetes, substance abuse and dementia.3,4,5 For more information about QUVIVIQ, see the Full Prescribing Information and Medication Guide Important Safety Information QUVIVIQ is a prescription medicine for adults who have trouble falling asleep or staying asleep (insomnia). Do not take QUVIVIQ if you fall asleep often at unexpected times (narcolepsy). QUVIVIQ may cause serious side effects, including:
QUVIVIQ is a federally controlled substance because it can be abused or lead to dependence. Before taking QUVIVIQ, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements
What should I avoid while taking QUVIVIQ?
QUVIVIQ may cause other serious side effects, including:
The most common side effects of QUVIVIQ are headache and sleepiness. These are not the only side effects of QUVIVIQ. Call your doctor for advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 Notes to the editor About Insomnia Insomnia is a condition of overactive brain activity during sleep, and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia. Insomnia is the most common sleep disorder, affecting more than 25 million adults in the US.6 Poor quality or insufficient sleep can affect many aspects of the daily lives of people with trouble sleeping including the ability to concentrate, mood and energy levels.2 In the long-term, insomnia is associated with numerous serious health conditions, such as psychiatric disorders, cardiovascular disease, type 2 diabetes, substance abuse and dementia.3,4,5 References
About Idorsia US About Idorsia Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe, Japan, and the US – the ideal constellation for bringing innovative medicines to patients. Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1,300 highly qualified specialists dedicated to realizing our ambitious targets. For further information, please contact US Media Global Investors & Media The above information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
SOURCE Idorsia Pharmaceuticals U.S. | ||
Company Codes: Swiss:IDIA |
View original content to download multimedia:
